Mylan's most recent trend suggests a bullish bias. One trading opportunity on Mylan is a Bull Put Spread using a strike $40.00 short put and a strike $35.00 long put offers a potential 7.53% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $40.00 by expiration. The full premium credit of $0.35 would be kept by the premium seller. The risk of $4.65 would be incurred if the stock dropped below the $35.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Mylan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Mylan is bullish.
The RSI indicator is at 74.33 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Mylan
Here's Who’s Getting Rich off Obamacare
Thu, 14 Nov 2013 13:25:22 GMT
Mylan Applauds New Federal Legislation to Increase Anaphylaxis Preparedness in Schools
Thu, 14 Nov 2013 13:05:40 GMT
noodls – PITTSBURGH, Nov. 14, 2013 /PRNewswire/ — Mylan Inc. (NASDAQ: MYL) commends federal legislation signed by President Barack Obama yesterday aimed at protecting people living with potentially life-threatening …
Mylan Applauds New Federal Legislation to Increase Anaphylaxis Preparedness in Schools
Thu, 14 Nov 2013 12:30:00 GMT
PR Newswire – PITTSBURGH, Nov. 14, 2013 /PRNewswire/ — Mylan Inc. (MYL) commends federal legislation signed by President Barack Obama yesterday aimed at protecting people living with potentially life-threatening allergies. The School Access to Emergency Epinephrine Act (H.R. 2094), encourages states to adopt laws allowing schools to maintain a supply of “stock,” or undesignated, epinephrine – the only first-line treatment for life-threatening allergic reactions (anaphylaxis). “Recent tragedies have reinforced that when anaphylaxis occurs, every minute matters and immediate access to epinephrine and emergency medical care is crucial. The new federal law is a critical step for improving anaphylaxis preparedness in schools,” said Heather Bresch, CEO of Mylan.
India's Strides Arcolab Q3 profit slumps; maintains outlook
Thu, 14 Nov 2013 10:15:05 GMT
Reuters – * Says expects Mylan deal to close by December * Says took remedial action on US FDA warning on Agila unit plant MUMBAI, Nov 14 (Reuters) – Strides Arcolab Ltd's September quarter profit plummeted on forex losses and a delay in regulatory approvals but the Indian drugmaker stood by its revenue forecast of 10 billion rupees ($157.5 million) for the year. The company said it had 18 pending approvals with the U.S. FDA and it expected to get nod for some of these products in the current quarter ending December.
S&P 500 hesitates at major resistance
Tue, 12 Nov 2013 17:30:42 GMT
MarketWatch – The S&P 500 Index continues to balk at significant resistance. The specific level rests at its all-time high of 1,775, and the S&P’s response to this area should set the near-term technical tone. Based …
Related Posts
Also on Market Tamer…
Follow Us on Facebook